Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy

Prostate Cancer Metastatic to Bone Clinical Trial

— RaRe  

Official title:

Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03458559
• Other study ID #: 2017.610
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: May 16, 2018
• Est. completion date: May 16, 2024

Study information

• Verified date: November 2020
• Source: VU University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Radium-223 chloride is an alpha-emitting radiopharmaceutical with proven survival benefit in patients with castration-resistant prostate cancer metastatic to bone. Beta-emitting radiopharmaceuticals have proven efficacy for palliating malignant bone pain. Nowadays, rhenium-188-HEDP is used in clinical practice for pain relief and palliative care. Several studies suggest that also rhenium-188-HEDP has the potential to improve overall survival. The purpose of this study is to investigate if treatment with rhenium-188-HEDP results in improvement of overall survival compared to treatment with radium-223-chloride.

Description:

The main objective of this trial is to compare rhenium-188-HEDP (a beta-emitting radiopharmaceutical) with radium-223-chloride (an alfa-emitting radiopharmaceutical), in patients with castration-resistant prostate cancer metastatic to bone, with overall survival as primary endpoint. For radium-223-chloride, an overall survival benefit has been proven in a large randomized phase III trial. Although such a trial has never been performed for rhenium-188-HEDP, some trials in literature suggest a survival benefit for rhenium as well. Rhenium has some advantages compared to radium. Firstly, it is easily available as it can be produced in the hospital. Secondly, the costs of rhenium are significantly lower compared to radium. Lastly, rhenium seems to have a favorable pain response. However, no randomized trials have been performed to confirm this.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 402
• Est. completion date: May 16, 2024
• Est. primary completion date: May 16, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male, 18 years or older
• Histologically confirmed prostate cancer
• Bone metastases (= 6 lesions) showing pathological uptake at bone scintigraphy.
• WHO performance status of =2
• Life expectancy of at least 6 months
• Castration-resistant disease: serum testosterone level of = 1.7 nmol per liter (=50 ng per deciliter) after bilateral orchiectomy or during maintenance treatment consisting of androgen-ablation therapy with a luteinizing hormone-releasing hormone agonist. During study treatment the maintenance androgen-deprivation therapy must be continued.
• Baseline PSA =5 ng/ml with evidence of progressively increasing PSA values
• Symptomatic disease with either regular use of analgesic medication or treatment with external-beam radiotherapy for cancer-related bone pain within the previous 12 weeks.
• Progression on or after treatment with docetaxel, or inability to receive docetaxel.
• Adequate renal function (serum creatinine level =1.5 x ULN)
• Adequate hematological function defined as absolute neutrophil count = 1.5x10^9/L and platelet count =100x 10^9/L)
• Written informed consent

Exclusion Criteria:

• Treatment with chemotherapy within the previous 4 weeks
• Continuation of treatment with abiraterone or enzalutamide
• Previous hemibody external radiotherapy
• Systemic radiotherapy with radioisotopes within the previous 24 weeks
• Malignant lymphadenopathy =3cm in the short-axis diameter
• Presence of visceral metastases
• Imminent of established spinal cord compression
• Active uncontrolled bacterial, viral or fungal infection
• History of another malignancy within the last five years except adequately treated basal cell carcinoma of the skin
• Organ allografts requiring immunosuppressive therapy.
• Any serious uncontrolled concommitant disease
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule: those conditions should be discussed with the patient before registration in the trial.

Related Conditions & MeSH terms

• Prostate Cancer Metastatic to Bone
• Prostatic Neoplasms

Intervention

Drug:
• Radium-223 chloride
Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations
• Rhenium-188-HEDP
Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations

Locations

Country	Name	City	State
Netherlands	VU University Medical Center	Amsterdam

Sponsors (1)

Lead Sponsor	Collaborator
VU University Medical Center

Country where clinical trial is conducted

Netherlands, 

References & Publications (3)

Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Guhlke S, Ezziddin S, Bucerius J, von Mallek D. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011 Nov;52(11):1721-6. doi: 10.2967/jnumed.111.093674. Epub 2011 Oct 5. — View Citation

Jong JM, Oprea-Lager DE, Hooft L, de Klerk JM, Bloemendal HJ, Verheul HM, Hoekstra OS, van den Eertwegh AJ. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. Eur Urol. 2016 Sep;70(3):416-26. doi: 10.1016/j.eururo.2015.09.005. Epub 2015 Sep 19. Review. — View Citation

Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr, Guhlke S, Biersack HJ. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003 Aug 1;21(15):2869-75. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Time from randomization until death due to any cause,	Time from randomization until death due to any cause, an average of 18 months
Secondary	Time to PSA progression	Time from randomization to the date of a minimum of rising PSA levels with an interval of >1week between each determination	Time from randomization to the date of a minimum of rising PSA levels, an average of 8 months (PSA measured at baseline and every 4 weeks).
Secondary	Time to total-ALP progression	Time from randomization to the date of earliest objective evidence of ALP progression.	Time from randomization to the date of earliest objective evidence of ALP progression, an average of 8 months (ALP measure at baseline and every 4 weeks)
Secondary	Clinical progression	Time from randomization to the date of first clinical progression.	Time from randomization to the date of first clinical progression, an average of 12 months
Secondary	Time to first SRE	Time from randomization to the date of first skeletal related events	Time from randomization to the date of first skeletal related events, an average of 12 months
Secondary	Quality of life	Measured by the EORTC quality of Life Questionnaire C30	Assessed through study completion, an average of 1 year
Secondary	Effect on pain	Measured with a visual analogue scale	Assessed through study completion, an average of 1 year
Secondary	Incremental Cost Effectiveness Ratio (IVER)	Ratio between the difference in costs and the difference in benefits (quality of life of treatment with rhenium-188-HEDP of radium-223-chloride)	Assessed through study completion, an average of 1 year